Develops immunotherapy medicines for cancer and skin diseases.
Dec 2025Revenue $336K/yrExpenses $5.63M/yr
No trendCash runway ≈ 6 months from Jun 2026
Figures by year
When will Provectus Biopharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $336K and expenses $5.63M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $336K | $5.63M | −$5.29M |
| Dec 2024 | $617K | $5.15M | −$4.53M |
| Dec 2023 | $558K | $3.46M | −$2.90M |
| Dec 2022 | $989K | $4.42M | −$3.43M |
| Dec 2015 | $0.00 | $24.7M | −$24.7M |
| Dec 2014 | $0.00 | $12.6M | −$12.6M |
| Dec 2013 | $0.00 | $13.0M | −$13.0M |
| Dec 2012 | $0.00 | $14.3M | −$14.3M |
| Dec 2011 | $0.00 | $21.4M | −$21.4M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.